Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
NHS England agrees funding for life-saving hepatitis C drug

NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

Published
12 hours ago
From
NHS England (press release)
Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is developed by Gilead Sciences, Inc.

Published
15 April 2014
From
Bristol-Myers Squibb press release
International Liver Conference: activists demand affordable hepatitis C treatment

As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in low and middle-income countries. Their protest targeted Gilead whose recently-approved direct-acting antiviral, Sovaldi, sells for USD $84,000.

Published
11 April 2014
From
HepCoalition
U.S. drug industry group defends price of Gilead hepatitis drug

The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

Published
11 April 2014
From
Reuters
Gilead Sciences: How serious is the pricing problem?

There really isn’t much precedent at all for branded companies competing on price in a MAJOR (~double digit) way. Plenty of companies play around with rebates and discounts, but it’s rare that the net price difference between major brands is more than a few percentage points.

Published
09 April 2014
From
Barron's
Gilead aims to license hepatitis C drug to 3-4 Indian firms

Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

Published
09 April 2014
From
Reuters
Express Scripts Raises Pressure on Gilead for Drug Price

Express Scripts Holding Co. (ESRX), a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi.

Published
08 April 2014
From
Bloomberg
Global Fund And Tiered Medicines Pricing Under Debate

The Global Fund to Fight AIDS, Tuberculosis and Malaria has launched an initiative with other agencies aimed at expanding global access to health products such as medicines. But the Fund has had some explaining to do about the initiative, which some say could encompass a plan to allow different prices based on national income levels.

Published
08 April 2014
From
Intellectual Property Watch
Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser Permanente

Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment price is "outrageous."

Published
03 April 2014
From
Reuters
Big Pharma Abandons New Tuberculosis Drug Research

Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Published
02 April 2014
From
CorpWatch.org
← First12345...64Next →

Filter by country